Last autumn, Abbott Laboratories held a community forum in
Chicago to present and discuss the latest information about problems occurring
during the manufacture of capsules of their protease inhibitor ritonavir
(Norvir™). All ritonavir recipients worldwide have been switched to an
oral formulation since.
Presentations from several of the company’s most senior staff can be read at
the website of the International Association of Physicians in AIDS Care (IAPAC),
host of the Norvir Advisory Committee, at
href="http://www.iapac.org/norvir">http://www.iapac.org/norvir